The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Go to Source
https://medicalxpress.com/rss-feed/
Go to Source
https://medicalxpress.com/rss-feed/